中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (3): 198-201.doi: 10.12144/zgmfskin202503198

• 临床研究 • 上一篇    下一篇

托法替布治疗获得性反应性穿通性胶原病一例并文献复习

付芳惠,马蕾,李媛,胡海友,张溪,高昱,付文静   

  1. 滨州医学院附属医院皮肤科，山东滨州，256603
  • 出版日期:2025-03-15 发布日期:2025-03-03

Acquired reactive perforating collagenosis successfully treated with tofacitinib: a case report and literature review

FU Fanghui, MA Lei, LI Yuan, HU Haiyou, ZHANG Xi, GAO Yu, FU Wenjing   

  1. Department of Dermatology, Binzhou Medical University Hospital, Binzhou 256603, China
  • Online:2025-03-15 Published:2025-03-03

PDF (PC)

25

摘要： 获得性反应性穿通性胶原病目前缺乏确切有效的治疗方法。托法替布是一种口服泛JAK抑制剂，可有效抑制JAK1和JAK3的活性，阻断多种炎性细胞因子的信号转导，从而用于炎症性皮肤病治疗。本文报道一例托法替布成功治疗获得性反应性穿通性胶原病的患者并进行文献复习。患者，男，24岁，因头面颈和肩背部丘疹、结节伴痒2个月就诊，给予枸橼酸托法替布口服，2个月后皮损消退，随访1年，未复发。

关键词: 托法替布, 获得性反应性穿通性胶原病, JAK抑制剂

Abstract: At present, there is a lack of effective treatment methods for acquired reactive perforating collagenosis. Tofacitinib, an oral pan-JAK inhibitor, can effectively inhibit the activity of JAK1 and JAK3 and block the signal transduction of a variety of inflammatory cytokines, thus playing a role in the intervention of inflammatory diseases. Herein, we report a patient with acquired reactive perforating collagenosis successfully treated with tofacitinib and review the relevant literature. A 24-year-old man presented with itchy papules and nodules on his head, neck, shoulders, and back. The skin rash disappeared after treated with tofacitinib for 2 months and no recurrence was observed during one-year follow-up.

Key words: tofacitinib, acquired reactive perforating collagenosis, JAK inhibitor